Literature DB >> 28780084

Nuclear maspin expression: A biomarker for budding assessment in colorectal cancer specimens.

Laura Banias1, Simona Gurzu2, Zsolt Kovacs3, Tivadar Bara4, Tivadar Bara4, Ioan Jung5.   

Abstract

AIM: To evaluate the maspin expression in colorectal carcinomas (CRC) and its possible role in quantification of the tumor budding.
METHODS: The tumor budding was prospectively quantified in 49 consecutive cases of patients that underwent surgical resection for CRC. The cases were divided in two groups: group A (n=23) - low budding (<5 tumor buds per high microscopic field) and group B (n=26) - high budding CRCs (≥5 buds). Maspin expression was evaluated in the tumor core and the buds from the hot spot area in 44 of the microsatellite stable adenocarcinomas. Its expression was quantified as negative, cytoplasmic only, nuclear only or mixed expression (cytoplasm and nucleus).
RESULTS: Compared with group A, a higher pT (p <0.0001) and pN stage (p=0.0001) and infiltrating aspect at macroscopic evaluation (p=0.0081) was identified in group B. No correlation between the maspin expression in the tumore core and the budding grade was noted (p=0.14). Compared with the tumor core, the cytoplasm to nuclear translocation of maspin was more frequently observed in cases from group B than A (n=0.0063).
CONCLUSION: For the colorectal carcinomas, the infiltrative aspect at macroscopic evaluation and nuclear maspin in the buds might be used as indicators of risk for lymph node metastases. Maspin nuclear expression in the buds may be helpful for a proper budding assessment and may serve as a negative prognostic factor.
Copyright © 2017 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Colorectal cancer; Maspin; Tumor budding

Mesh:

Substances:

Year:  2017        PMID: 28780084     DOI: 10.1016/j.prp.2017.07.025

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

Review 1.  Tumour budding in solid cancers.

Authors:  Alessandro Lugli; Inti Zlobec; Martin D Berger; Richard Kirsch; Iris D Nagtegaal
Journal:  Nat Rev Clin Oncol       Date:  2020-09-08       Impact factor: 66.675

2.  Impact of primary tumour location on colorectal liver metastases: A systematic review.

Authors:  George Bingham; Alysha Shetye; Reena Suresh; Reza Mirnezami
Journal:  World J Clin Oncol       Date:  2020-05-24

Review 3.  Subcellular Expression of Maspin in Colorectal Cancer: Friend or Foe.

Authors:  Simona Gurzu; Ioan Jung
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

4.  Up-frameshift Protein 1 Promotes Tumor Progression by Regulating Apoptosis and Epithelial-Mesenchymal Transition of Colorectal Cancer.

Authors:  Binlie Chen; Huaiming Wang; Danfeng Li; Xiaosheng Lin; Zhiyan Ma; Yongming Zeng
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

5.  Application of Prognostic Models Based on Psoas Muscle Index, Stage, Pathological Grade, and Preoperative Carcinoembryonic Antigen Level in Stage II-III Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy.

Authors:  Li Shan; Tian Li; Wenhao Gu; Yuting Gao; Erdong Zuo; Huizhu Qiu; Rong Li; Xu Cheng
Journal:  J Oncol       Date:  2022-02-02       Impact factor: 4.375

6.  In-House Validated Map of Lymph Node Stations in a Prospective Cohort of Colorectal Cancer: A Tool for a Better Preoperative Staging.

Authors:  Patricia Simu; Ioan Jung; Laura Banias; Zsolt Zoltan Fulop; Tivadar Bara; Iunius Simu; Sebastian Andone; Raluca Ioana Stefan-van Staden; Catalin Bogdan Satala; Ioana Halmaciu; Simona Gurzu
Journal:  J Oncol       Date:  2022-03-19       Impact factor: 4.375

Review 7.  From Dukes-MAC Staging System to Molecular Classification: Evolving Concepts in Colorectal Cancer.

Authors:  Laura Banias; Ioan Jung; Rebeca Chiciudean; Simona Gurzu
Journal:  Int J Mol Sci       Date:  2022-08-21       Impact factor: 6.208

8.  Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition.

Authors:  Laura Banias; Ioan Jung; Tivadar Bara; Zsolt Fulop; Patricia Simu; Iunius Simu; Catalin Satala; Simona Gurzu
Journal:  Oncol Lett       Date:  2019-12-18       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.